AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, which is a significant global health issue [1][8]. Rights Offering Details - Each subscription right allows holders to purchase one unit, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, at a subscription price of $1,000 per unit [2]. - The Preferred Stock is convertible into 1,000 shares of Common Stock at the holder's option, with a conversion price of $1.00 per share [2]. - Each Warrant can be exercised for one share of Common Stock at an exercise price of $1.00 per share, valid for five years from issuance [2]. Participation Requirements - Record holders wishing to participate must submit a completed rights certificate and payment to the Subscription Agent by 5:00 p.m. Eastern Time on March 3, 2026 [3]. - Subscription rights are non-transferable and cannot be revoked once exercised [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the Rights Offering [5]. - The offering is conducted under a registration statement declared effective by the SEC on February 10, 2026, and is available through the SEC's website [6]. Company Overview - AIM ImmunoTech Inc. focuses on immuno-pharmaceutical research and development, particularly for Ampligen®, which is a dsRNA and selective TLR3 agonist with demonstrated activity in clinical trials [8][9].